BioStock:Abliva increases awareness of mitochondrial diseases

Report this content

As the world observes Mitochondrial Disease Week, the spotlight is on the debilitating symptom of fatigue that plagues people with mitochondrial disease. Lund-based biotech company Abliva is at the forefront of this battle with its drug candidate KL1333, currently in a global phase II study. BioStock contacted Abliva’s Chief Medical Officer Magnus Hansson to learn more about the company’s work in close cooperation with patient organisations.

Read the article at

This is a press release from BioStock - Connecting Innovation & Capital


Documents & Links

Quick facts

BioStock: Abliva increases awareness of mitochondrial diseases
Tweet this